Exclusive live coverage from day five of the American Society of Clinical Oncology’s annual meeting in Chicago.
• To view all of our coverage from the preeminent cancer event, produced in association with Kantar Health, as well as additional content, visit the Spotlight on ASCO 2019 and the future of oncology
On the agenda for Tuesday:
- An oral presentation will discuss results of a phase 2 trial of Ipsen/Exelixis’ cabozantinib vs. chemotherapy, based on data from the phase 2 Alliance A091201 study in metastatic and primary uveal melanoma.
View the live coverage from day five at ASCO 2019 below (the live blog may take a few seconds to load):
Joan Mancuso@2020VisionGirlDr. Jeff Peppercorn discussing the constant struggle between access to treatment and development of evidence in the interest of time in MBC, at the controversies in MBC session this morning. @EthicsdoctorP @ASCO #mbcstrength #asco19 pic.twitter.com/AwpAYxqqeu
Prof Patel also mentioned data from Eli Lilly’s Verzenio (abemaciclib), which is showing promise in dedifferentiated liposarcomas.
Privately held biotech Aadi Bioscience is also developing nab-Sirolimus in a rare sarcoma called advanced PEComa (perivascular epithelioid cell tumour) where there is no approved therapy.
This produced a 42% overall response rate in 31 patients and 62% of patients were still on trial after a year. 35% of patients had stable disease, and disease control rate was 77%.
Aadi expects to file data with the FDA late this year or early next year, and the drug has already been earmarked as a Breakthrough Therapy, setting up a potential six-month priority review.
Just
attended a session on sarcoma, from Professor Shreyaskumar Patel, of the University of Texas MD Anderson Center, on the rare cancer sarcoma. There are some target-specific treatments that are under investigation.
One of these in Epizyme’s taxemetostat, which the biotech just filed with the FDA in epithelioid sarcomas.
Findings of a phase 2 study used for the filing include a 15% objective response rate (ORR) and a 26% disease control rate (DCR).
The median duration of response (DOR) has not yet been reached.
AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC).
Latest results show a durable and sustained OS benefit in patients with unresectable, Stage III NSCLC who had not progressed following concurrent chemoradiation therapy (CRT), a previous standard-of-care (SoC) treatment.
The OS rate was 57% at three years for patients receiving Imfinzi vs. 43.5% for placebo following concurrent CRT. Median OS was not yet reached with the Imfinzi arm vs. 29.1 months for placebo.
Good morning from Chicago. ASCO is winding up now but there is still some late breaking data coming through.
Bristol-Myers Squibb just announced results of the phase 1/2 CheckMate – 040 study, testing Opdivo (nivolumab) and Yervoy (ipilimumab) in hepatocellular carcinoma (HCC) previously treated with Bayer’s Nexavar (sorafenib).
After 28-month follow up the objective response rate was 31% based on a standard tumour evaluation.
Data were featured on a poster display summarising findings of the study of 148 patients, split into three arms testing different doses.
The best overall survival came from an arm with a lower dose of nivo, and a higher dose of ipi, where overall survival was 22.8 months. At 30 months the overall survival rate was 44% and responses were achieved regardless of PD-L1 status.
There were the usual safety issues expected from this combination such as itchy skin and diarrhoea.
Merry-Jennifer Markham@DrMarkhamI may say this every year, but it’s worth repeating. Thank you to all patients who participated in the research that makes #ASCO19 and progress in cancer care possible. We owe you our gratitude, and we’ll continue to work hard to make outcomes better.
Only 3% of patients with cancer in the US enrol on a clinical trial – and the American Society of Clinical Oncology (ASCO) is concerned that outdated and restrictive eligibility criteria could be hindering research.
The organisaton has used its annual meeting in Chicago to call for some of these outmoded eligibility criteria to be dropped after a study showed that relaxing three rules used to screen patients almost doubled the number of patients on a dummy lung cancer trial.
Antonio Passaro MD PhD@APassaroMD#ASCO19 #LCSC #OncoAlerOne of the best presentstion of this ASCO. A very excellent discussion of @christine_lovly about EGFR exon 20 insertions.
Yesterday orphan, today very potentially druggable mutations!!
The power of clinical and translational #researchpic.twitter.com/muTiRryExX
At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) enfortumab vedotin in relapsed patients with locally advanced or metastatic bladder cancer.
The data presented were from Cohort 1 of the trial, which evaluated enfortumab in relapsed patients who had been treated with a platinum and a checkpoint inhibitor. Kantar’s Len Kusdra reviews the study in this video.
Sanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 candidate isatuximab in multiple myeloma, already filed in the US and Europe.
Headline results from the first phase 3 ICARIA-MM trial of isatuximab were reportedearlier this year, but the actual data was revealed for the first time at the ASCO congress in Chicago – and according to analyst Vamil Divan at Credit Suisse looks “strong” and “pivotal”, likely setting up approvals.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.